Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide
Authors:
- Christopher SchmicklCSChristopher Schmickl
- Athiwat TripipitsiriwatATAthiwat Tripipitsiriwat
- Babak MokhlesiBMBabak Mokhlesi
- Monica MallampalliMMMonica Mallampalli
- Brandon NokesBNBrandon Nokes
- Vaishnavi KundelVKVaishnavi Kundel
- Kathy PageKPKathy Page
- Christina FinchCFChristina Finch
- Lucas DonovanLDLucas Donovan
- Mira TadrosMTMira Tadros
- Ravi AysolaRARavi Aysola
- Andrey ZinchukAZAndrey Zinchuk
Preprint
Abstract
Purpose Approximately one of ten US adults has comorbid obesity and obstructive sleep apnea (COBOSA). Traditionally, sleep medicine management of COBOSA focused on continuous positive airway pressure (CPAP). Recently, tirzepatide (a once-weekly injection) was approved for COBOSA after demonstrating substantial reduction of weight and OSA severity in efficacy trials. We assessed patient and provider attitudes towards these therapies for COBOSA. Methods We conducted an online survey (November 2024–August 2025) targeting US adults with OSA and/or obesity (“patients”) and sleep medicine providers. The survey assessed treatment acceptability, preferences, and informational needs. Results The main analysis included 461 patients (86% with sleep apnea diagnosis, 49% with COBOSA) and 114 providers. Overall, 70% of respondents found both CPAP and tirzepatide at least somewhat acceptable, with significantly different response patterns (P<.001): providers found CPAP more acceptable than tirzepatide, whereas patients rated both therapies similar. When asked to choose a preferred long-term therapy assuming equal effectiveness, patients favored tirzepatide (48% vs 21%), while providers preferred CPAP (52% vs 27%). Providers with experience prescribing injectable weight-loss medications were more aligned with patient views. Both groups supported combination therapy, though patients were less enthusiastic than providers (61% vs 86%). Both groups valued a wide range of outcomes for decision making—across symptom, sleep, and cardiometabolic health domains—and emphasized the importance of safety, long-term data, and costs. Conclusions Patients and providers view CPAP and/or tirzepatide as acceptable options for COBOSA, but preferences diverge. Given equipoise, comparative effectiveness trials are urgently needed to guide individualized treatment strategies. Current Knowledge/Study Rationale The weight-loss medication tirzepatide has recently emerged as a potential treatment option for patients with obstructive sleep apnea (OSA) and comorbid obesity (COBOSA), but little is known about patient and provider attitudes toward this therapy compared with the current first-line treatment of continuous positive airway pressure (CPAP) or what information they need to make informed choices between these options. Study Impact This survey demonstrates high levels of acceptability for both tirzepatide and CPAP, supporting clinical equipoise. It also highlights the priorities, concerns, and decision-making factors most relevant to patients and providers, providing a foundation for future comparative trials and implementation efforts that are aligned with stakeholder needs and preferences.Keywords
This publication has 67 references indexed in Scilit:
- The relationship between obesity and obstructive sleep apnea in four community-based cohorts: an individual participant data meta-analysis of 12,860 adultseClinicalMedicine, 2025
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or ObesityJAMA Network Open, 2025
- Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity CareJournal of the Academy of Nutrition and Dietetics, 2024
- GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 DiabetesJAMA Network Open, 2024
- Survey Protocols, Response Rates, and Representation of Underserved PatientsJAMA Health Forum, 2024
- Sleep Apnea and InsomniaChest, 2021
- Responsiveness of Patient-Reported Outcomes to Treatment Among Patients With Type 2 Diabetes Mellitus and OSAChest, 2020
- Insomnia and Obstructive Sleep ApneaSleep Medicine Clinics, 2013
- Effectiveness of Treatment Apnea-Hypopnea Index: A Mathematical Estimate of the True Apnea-Hypopnea Index in the Home SettingJournal of Oral and Maxillofacial Surgery, 2013
- Association Between Treated and Untreated Obstructive Sleep Apnea and Risk of HypertensionJAMA, 2012